NuVasive, Inc. – NASDAQ:NUVA

Financial Health
0
1
2
3
4
5
6
7
8
9

NuVasive stock price monthly change

-1.90%
month

NuVasive stock price quarterly change

+7.08%
quarter

NuVasive stock price yearly change

-6.49%
year

NuVasive key metrics

Market Cap
2.08B
Enterprise value
2.97B
P/E
56.03
EV/Sales
2.47
EV/EBITDA
13.73
Price/Sales
1.84
Price/Book
2.55
PEG ratio
0.34
EPS
0.54
Revenue
1.22B
EBITDA
189.78M
Income
28.45M
Revenue Q/Q
2.36%
Revenue Y/Y
4.43%
Profit margin
3.36%
Oper. margin
6.94%
Gross margin
72%
EBIT margin
6.94%
EBITDA margin
15.48%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

NuVasive stock price history

NuVasive stock forecast

NuVasive financial statements

NuVasive, Inc. (NASDAQ:NUVA): Profit margin
Sep 2022 295.28M -1.97M -0.67%
Dec 2022 305.44M 24.07M 7.88%
Mar 2023 307.71M -1.01M -0.33%
Jun 2023 317.78M 7.36M 2.32%
NuVasive, Inc. (NASDAQ:NUVA): Debt to assets
Sep 2022 2174945000 1.34B 61.74%
Dec 2022 2224505000 1.35B 60.94%
Mar 2023 2167154000 1.29B 59.69%
Jun 2023 2089550000 1.19B 57.29%
NuVasive, Inc. (NASDAQ:NUVA): Cash Flow
Sep 2022 54.25M -39.52M -496K
Dec 2022 46.77M -40.97M 1.57M
Mar 2023 1.97M -35.14M -34.90M
Jun 2023 36.51M -40.09M -96.80M

NuVasive alternative data

NuVasive, Inc. (NASDAQ:NUVA): Employee count
Aug 2023 3,000
Sep 2023 3,000
Oct 2023 3,000
Nov 2023 3,000
Dec 2023 3,000
Jan 2024 3,000
Feb 2024 3,000
Mar 2024 3,000
Apr 2024 3,000
May 2024 3,000
Jun 2024 3,000
Jul 2024 3,000

NuVasive other data

100.00% 0.00%
of NUVA is owned by hedge funds
52.23M -431.29K
shares is hold by hedge funds

NuVasive, Inc. (NASDAQ:NUVA): Insider trades (number of shares)
Period Buy Sel
May 2021 0 5607
Jun 2021 0 10000
Mar 2022 0 5000
Apr 2022 0 5000
Transaction Date Insider Security Shares Price per share Total value Source
Option
HARBAUGH MATTHEW K officer: EVP and .. RSUs 12,190 N/A N/A
Option
SISITSKY NATHANIEL officer: SVP & Ge.. RSUs 5,333 N/A N/A
Option
WOLF DALE A. officer: SVP, Global Operations
RSUs 4,572 N/A N/A
Option
FARRINGTON MICHAEL officer: SVP, People and Culture
RSUs 1,905 N/A N/A
Option
FARRINGTON MICHAEL officer: SVP, People and Culture
Common Stock 1,905 N/A N/A
Option
WOLF DALE A. officer: SVP, Global Operations
Common Stock 4,572 N/A N/A
Option
ROSENBAUM MARC W. officer: Chief Accounting Officer
RSUs 1,829 N/A N/A
Option
ROSENBAUM MARC W. officer: Chief Accounting Officer
Common Stock 1,829 N/A N/A
Option
SISITSKY NATHANIEL officer: SVP & Ge.. Common Stock 5,333 N/A N/A
Option
BARRY JAMES CHRISTOPHER director, officer: Chief Execut..
RSUs 34,284 N/A N/A
Patent
Grant
Filling date: 23 Oct 2020 Issue date: 20 Sep 2022
Grant
Filling date: 25 Feb 2020 Issue date: 20 Sep 2022
Grant
Filling date: 20 Aug 2019 Issue date: 9 Aug 2022
Application
Filling date: 25 Apr 2022 Issue date: 4 Aug 2022
Application
Filling date: 12 Apr 2022 Issue date: 4 Aug 2022
Grant
Filling date: 21 Apr 2020 Issue date: 2 Aug 2022
Grant
Filling date: 5 Sep 2019 Issue date: 2 Aug 2022
Grant
Filling date: 6 Jun 2019 Issue date: 2 Aug 2022
Application
Filling date: 15 Apr 2022 Issue date: 28 Jul 2022
Grant
Filling date: 23 Oct 2019 Issue date: 19 Jul 2022
Insider Compensation
Mr. J. Christopher Barry (1973) Chief Executive Officer & Director
$1,440,000
Mr. Matthew K. Harbaugh (1970) Executive Vice President & Chief Financial Officer $1,020,000
Mr. Nathaniel B. Sisitsky Esq. (1974) Senior Vice President, Gen. Counsel & Corporation Sec. $594,940
Saturday, 15 June 2024
seekingalpha.com
Thursday, 31 August 2023
zacks.com
Wednesday, 30 August 2023
prnewswire.com
Monday, 28 August 2023
prnewswire.com
Thursday, 3 August 2023
zacks.com
Wednesday, 2 August 2023
seekingalpha.com
zacks.com
prnewswire.com
Thursday, 27 July 2023
GuruFocus
Thursday, 11 May 2023
Zacks Investment Research
Wednesday, 10 May 2023
Seeking Alpha
Zacks Investment Research
Thursday, 4 May 2023
Seeking Alpha
Monday, 1 May 2023
Zacks Investment Research
Wednesday, 26 April 2023
Zacks Investment Research
Tuesday, 25 April 2023
Zacks Investment Research
Friday, 24 March 2023
Zacks Investment Research
Tuesday, 21 March 2023
Zacks Investment Research
Friday, 17 March 2023
Zacks Investment Research
Thursday, 2 March 2023
Zacks Investment Research
Monday, 27 February 2023
PRNewsWire
Thursday, 23 February 2023
Zacks Investment Research
Wednesday, 22 February 2023
Seeking Alpha
Zacks Investment Research
Sunday, 12 February 2023
Seeking Alpha
Thursday, 9 February 2023
Barrons
Market Watch
Friday, 13 January 2023
Zacks Investment Research
Wednesday, 28 December 2022
Seeking Alpha
Thursday, 17 November 2022
Zacks Investment Research
  • When is NuVasive's next earnings date?

    Unfortunately, NuVasive's (NUVA) next earnings date is currently unknown.

  • Does NuVasive pay dividends?

    No, NuVasive does not pay dividends.

  • How much money does NuVasive make?

    NuVasive has a market capitalization of 2.08B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 5.53% to 1.2B US dollars.

  • What is NuVasive's stock symbol?

    NuVasive, Inc. is traded on the NASDAQ under the ticker symbol "NUVA".

  • What is NuVasive's primary industry?

    Company operates in the Healthcare sector and Medical - Devices industry.

  • How do i buy shares of NuVasive?

    Shares of NuVasive can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are NuVasive's key executives?

    NuVasive's management team includes the following people:

    • Mr. J. Christopher Barry Chief Executive Officer & Director(age: 52, pay: $1,440,000)
    • Mr. Matthew K. Harbaugh Executive Vice President & Chief Financial Officer(age: 55, pay: $1,020,000)
    • Mr. Nathaniel B. Sisitsky Esq. Senior Vice President, Gen. Counsel & Corporation Sec.(age: 51, pay: $594,940)
  • How many employees does NuVasive have?

    As Jul 2024, NuVasive employs 3,000 workers.

  • When NuVasive went public?

    NuVasive, Inc. is publicly traded company for more then 21 years since IPO on 13 May 2004.

  • What is NuVasive's official website?

    The official website for NuVasive is nuvasive.com.

  • Where are NuVasive's headquarters?

    NuVasive is headquartered at 7475 Lusk Boulevard, San Diego, CA.

  • How can i contact NuVasive?

    NuVasive's mailing address is 7475 Lusk Boulevard, San Diego, CA and company can be reached via phone at 858 909 1800.

NuVasive company profile:

NuVasive, Inc.

nuvasive.com
Exchange:

NASDAQ

Full time employees:

3,000

Industry:

Medical - Devices

Sector:

Healthcare

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

7475 Lusk Boulevard
San Diego, CA 92121

CIK: 0001142596
ISIN: US6707041058
CUSIP: 670704105